H.C. Wainwright Reaffirms Their Buy Rating on IntelGenx Technologies (IGXT)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on IntelGenx Technologies (IGXT) today and set a price target of $1. The company’s shares closed on Friday at $0.41, close to its 52-week low of $0.39.

According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -11.9% and a 28.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Gritstone Oncology Inc, Trillium Therapeutics, and Leap Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IntelGenx Technologies with a $1.25 average price target, a 206.1% upside from current levels. In a report issued on August 9, Maxim Group also maintained a Buy rating on the stock with a $1.50 price target.

See today’s analyst top recommended stocks >>

Based on IntelGenx Technologies’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $2.6 million. In comparison, last year the company had a GAAP net loss of $2.4 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

IntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. Its products include rizaport, tadalafil, loxapine, and montelukast.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts